# Shaping science: Scholarly motivation and research outcomes in NIH-HEAL funded studies

**Authors:** Bryce Kushmerick-McCune, Ginnie Sawyer-Morris, Merve Ulukaya, Kendra Clark, Scott T. Walters, Faye S. Taxman

PMC · DOI: 10.1371/journal.pone.0343417 · PLOS One · 2026-03-03

## TL;DR

This study explores what NIH-HEAL funded researchers consider important in pain and addiction research, revealing common priorities and implications for science and clinical practice.

## Contribution

The study provides novel insights into how research priorities in pain and addiction are shaped by analyzing funded NIH-HEAL abstracts.

## Key findings

- NIH-HEAL funded studies show a preference for prescription medication in treating pain and opioid use disorder.
- A significant portion of studies focus on intervention efficacy rather than broader outcomes.
- The analysis highlights the influence of researchers' values on shaping scientific priorities and clinical policies.

## Abstract

In 2018, the National Institutes of Health (NIH) launched the Helping to End Addiction Long-Term ® (HEAL) Initiative to advance addiction and pain research and clinical practice. The NIH-HEAL Initiative supports investigator-initiated research across diverse focus areas, allowing scientists discretion in selecting research topics, methodologies, and outcomes while still remaining subject to NIH’s peer review process. This study aims to answer the research question: what do investigators of NIH-HEAL funded studies define as important knowledge, particularly in relation to growth in empirical studies and clinical policy? By examining how pain and addiction researchers define what knowledge is important to produce, this study offers novel insight into how research priorities take shape and why this matters for science and clinical practice. To answer this research question, we conducted a directed content analysis of 1,068 NIH-HEAL funded study abstracts published on the NIH RePORTER website. Our findings suggest that while the scope of the NIH-HEAL funded studies is broad, there are common identifiable patterns that exist within the funded research portfolio such as a preference for treating pain and addiction conditions with prescription medication (33.80% of pain studies, 34.17% of opioid use disorder studies) and a narrow focus on intervention efficacy (43.21% of pain studies, 39.22% of opioid use disorder studies). This analysis is important for the scientific enterprise and clinical practice as prior literature has painted research as inherently influenced by the values of a scientist and of their discipline. By identifying what social and empirical problems NIH-HEAL funded investigators identify, their proposed solutions, and the outcomes they prioritize, this study carries important implications for grant-funding agencies, scientists, and the people who need and receive treatment for pain and addiction conditions.

## Full-text entities

- **Genes:** OPRM1 (opioid receptor mu 1) [NCBI Gene 4988] {aka LMOR, M-OR-1, MOP, MOR, MOR1, OPRM}, TIAM1 (TIAM Rac1 associated GEF 1) [NCBI Gene 7074] {aka NEDLDS, TIAM-1}
- **Diseases:** addictive behavior (MESH:D000437), Pain (MESH:D010146), peripheral nerve injury (MESH:D059348), craving (MESH:C564883), anxiety (MESH:D001007), postoperative pain (MESH:D010149), impaired neurodevelopment (MESH:D060825), Alzheimer's (MESH:D000544), Addiction (MESH:D019966), fatigue (MESH:D005221), PAIN (MESH:D009477), respiratory depression (MESH:D012131), analgesia (MESH:D000699), chronic low back pain (MESH:D017116), post-traumatic stress disorder (MESH:D013313), OUD (MESH:D009293), deaths (MESH:D003643), opioid overdose (MESH:D000083682), neonatal abstinence syndrome (MESH:D009357), constipation (MESH:D003248), liver toxicity (MESH:D056486), depression (MESH:D003866), breast cancer (MESH:D001943), chronic back pain (MESH:D059350), kidney toxicity (MESH:D007674), neuropathic pain (MESH:D009437), drug overdose (MESH:D062787), cancer pain (MESH:D000072716), opioid tolerance (MESH:D018149), HIV (MESH:D015658)
- **Chemicals:** brexpiprazole (MESH:C000591922), oligonucleotides (MESH:D009841), methadone (MESH:D008691), 1R01DA056658 (-), heroin (MESH:D003932), Naltrexone (MESH:D009271), cocaine (MESH:D003042), alcohol (MESH:D000438), Buprenorphine (MESH:D002047)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12956126/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12956126/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC12956126/full.md

---
Source: https://tomesphere.com/paper/PMC12956126